Luc Marengere

About

Dr. Luc Marengère joined TVM Partners in 2012 and serves as a Managing Partner. He is responsible for TVM Partners' overall investment strategy and global fund operations. Luc has over 25 years of venture capital experience and is a key driver of the investment strategy for TVM LSI I and TVM LSI II Funds. He is a Director on the Boards of Panthera Dental, Egg Medical, Kent Imaging, Emovi and Access Vascular as well as early-stage companies Vespina, Occellaris and Auricula. Previously, Luc was a Director on the Board of NASDAQ listed Acer Therapeutics (sold to Zevra Tharapeutics) and Colucid Pharma Inc. (sold to Eli Lilly for US$960M) as well as privately held Aurka Pharma Inc. (sold to Eli Lilly for US$575M; total value includes upfront plus CVRs) and Acanthas Pharma (sold to Eli Lilly for US$430M; total value includes upfront plus CVRs). Before TVM, Luc was Managing Partner at Toronto-based VG Partners where he founded the life science investment practice, with notable deals including Cytochroma Inc. (sold to Opko for US$400M); VisualSonics (sold to Sonosite for US$75M), CITA Neuropharma (sold to Vernalis Plc for US$85M) and Trillium Therapeutics (sold to Pfizer for US$2.2B). Prior to VG Partners, Luc focused on venture investments in the life science sector at Montreal-based Caisse De Depot (CDP) as well as MDS Capital and MedTech Partners. Earlier in his career, he conducted commercially oriented research in immunology and oncology at Amgen. Luc holds a Ph.D. from University of Toronto (Medical Biophysics and Molecular Genetics), a Master’s degree from Queen’s University (Biochemistry) and a degree from University of Ottawa (Bachelor’s degree, Biochemistry, Magna Cum Laude).